Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07231653

Home Monitoring Study for Surgical Patients

This clinical trial is designed to evaluate the accuracy, usability, and patient compliance of the Wellvii VitalDetect, an FDA-cleared (510(k) K231625), Class II medical device intended for non-invasive monitoring of vital signs including blood pressure, pulse rate, and temperature. The study will focus on comparing measurements obtained in a home environment using the device to those collected in a clinical setting, with the goal of validating the device's performance for real-world, at-home use.

The Wellvii VitalDetect is a portable, battery-operated, spot-check monitor that uses finger-based technology for most parameters and an infrared sensor for forehead-based, non-contact temperature readings. It is designed for use by adults (18 years or older) in a home environment and is not intended for continuous monitoring. In addition to the cleared vital signs, the device displays other wellness parameter for general health tracking. A smartphone application supports the user experience by delivering usage instructions and data display.

The study will assess:

* Measurement accuracy compared to standard clinical instruments * Patient ease-of-use and engagement with the device * Adherence to regular self-monitoring schedules * Overall user satisfaction and confidence I home-based monitoring

This research will contribute to the growing body of evidence supporting remote patient monitoring solutions and aims to advance the adoption of decentralized technology-enabled healthcare delivery.

The study aligns with Wellvii Inc.'s mission to transform healthcare delivery by enabling continuous, connected health monitoring from the home. The ultimate goal is to empower patients and healthcare providers with real-time, clinically actionable health at a that can lead to earlier intervention, improved outcomes, and reduced system burden.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Patient Monitoring Postoperative Period

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinically stable patients requiring routine postoperative monitoring in the absence of any acute illness following surgery.
  • Able to use a smartphone or tablet for the monitoring system.

Exclusion criteria

  • Severe cognitive impairment or conditions that may interfere with the use of home monitoring devices.
  • Currently participation in other clinical trials involving vital sign monitoring.
  • Unable to provide informed consent.

Treatment and study plan

Home-based Vital Sign Monitoring

Device

Postoperative surgical patient will use the Wellvii VitalDetect, an FDA-cleared, non-invasive, handheld device for home-based monitoring of blood pressure, pulse rate, and temperature. After receiving training at discharge and recording baseline vital signs in clinic, participants will monitor their vital signs twice daily for two weeks using the device and a companion mobile app. Weekly clinic visits will collect corroborating data. The device does not requires calibration or maintenance and provides results in under 90 seconds. Usability and satisfaction will be assessed through questionnaires, and compliance will be monitored via app logs. Data will be automatically uploaded to a secure, de-identified database for analysis.

Primary outcomes

  1. Accuracy of Home-Based Vital Sign Monitoring Compared to Standard Clinical Measurements

    Time frame: For a two-week period (twice daily) following their discharge from hospital.

    This outcome measures the accuracy of vital sign readings (temperature, blood pressure, and heart rate) collected at home using the Wellvii VitalDetect™ compared to standard clinical equipment readings taken during weekly hospital visits. Accuracy will be evaluated using paired t-tests to compare mean differences between home and clinical measurements.

Secondary outcomes

  1. Patient Compliance with Home Monitoring Protocol

    Time frame: At one and two weeks post-hospital discharge

    This outcome assess participant compliance with the home monitoring protocol, defined as the percentage of days during the two-week study period in which complete vital sign measurements are successfully recorded using the device and app.

Other outcomes

  1. Patient satisfaction with Home Monitoring Protocol

    Time frame: At the one-week and two-week clinic visits

    Satisfaction will be assessed using a Likert-scale questionnaire. The questionnaire evaluates overall satisfaction with the device.

Study contacts

Contact information is provided by the study sponsor or research team.

Carolina Archundia-Herrera, PhD

CONTACT

[email protected]

(587) 982-6635

Todd McMullen, MD

CONTACT

[email protected]

(780) 407-1108

Sponsors and collaborators

Lead sponsor

University of Alberta

Other

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2027
First posted
Nov 17, 2025
Registry last updated
May 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.